EXEL vs PATH · P/E 17, rev $2.17B vs P/E 19, rev $1.61B
Exelixis Inc (EXEL) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Exelixis Inc (EXEL) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported EXEL revenue for 2025-01-03 was $2.17B. Net income was $521.3M. Revenue was up 18.5% from 2023-12-29 to 2025-01-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the EXEL and PATH stock pages for the full models.
Not investment advice.